TOP AGO TUMOR SECRETS

Hormonal therapy remains the remedy of first option for metastatic sufferers with endocrine-responsive breast cancer (LoE 1a A, AGO ++). The sequential use of the available medications is dependent upon the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at time of analysis of relapse is suggested whenever attainable, to b